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Abstract
Foot osteoarthritis (OA) is a very common disease that mainly affects older people deeply influencing their quality of 
life. The joint most frequently involved in the articular degenerative process is the first metatarsophalangeal joint. Its severe 
impairment may lead to a specific clinical pattern known as hallux rigidus that often requires surgical treatment. Currently 
conventional radiograms of feet associated with an accurate clinical examination should be performed in order to diagnose 
foot OA. However, new imaging modalities as ultrasonography and magnetic resonance imaging are emerging as valuable 
tools to assess foot OA. Therapeutic options for foot OA consist of conservative strategies, including life-style modification 
and pharmacological treatment, options that are usually adopted in early-stage disease and in invasive surgical procedures 
reserved to late-stage conditions. At the present time there is a lack of evidence in international literature specifically dealing 
with foot OA, so further investigation on this topic is required to clarify its pathogenesis, the diagnostic pathway and the best 
clinical management.
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Osteoarthritis (OA) is a degenerative disorder that re-
sults from the biochemical breakdown of articular carti-
lage in the synovial joints and is the commonest cause of 
arthritis and a leading cause of pain and disability world-
wide [1]. 
Biomechanical and biochemical factors, such as the 
production of several chemokines, cytokines, and growth 
factors, determine an aberrant chondrocyte activation 
that contributes to the disruption of articular homeosta-
sis. The imbalance between pro- and anti-inflammatory 
molecules may influence the progression of cartilage 
damage [2]. 
OA accounts for 15% of all musculoskeletal consulta-
tions in patients aged 45 years and over in primary care 
[3]. This degenerative articular disease predominantly af-
fects the knees, hips, hands and feet. Whereas the knee, 
the hip and the hand have received considerable atten-
tion, the foot has been relatively neglected yet the first 
metatarsophalangeal joint is one of the joints most fre-
quently affected by OA [4].
The aim of this review is to provide an overview of 
the current knowledge on foot OA, concerning risk fac-
tors, clinical features, diagnosis and treatment.
Epidemiology and pathomechanism 
OA is the leading cause of chronic pain and disability 
among older people in developed countries. A podiatric 
supplement to the US National Health Interview Survey 
estimated that 24% of the population has at least one foot 
ailment, with older adults experiencing more troubles 
than younger adults [5]. Recent prevalence data from the 
Framingham Study reported that 19% of men and 29% 
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of women reported foot pain on most days of the month, 
with prevalence of pain at specific foot locations ranging 
from 7% to 13% [6].
The foot is involved with a variable frequency accord-
ing to the joint sites, hindfoot OA is quite uncommon, 
but forefoot OA is a frequent joint disease, particularly at 
the level of the first metatarsophalangeal joint, that rep-
resents the prime site of OA changes. It is estimated that 
OA of the big toe joint affects 35% to 60% of adults aged 
over 65 years [7].
The midfoot is rarely involved in OA alterations and 
only few research groups have described non-Charcot ar-
thropathy of the midfoot, including patients with primary 
OA in this joint site [8-10].
The literature suggests that midfoot OA is usually 
post-traumatic. Midfoot injuries affect approximately 
55,000 people per year and are commonly seen in the 
athletic population [11]. Despite their seemingly low in-
cidence, they are particularly important because as many 
as 20% are missed or misdiagnosed [12].
Moreover OA of the tarsometatarsal joints has 
emerged as a challenging problem due to its high poten-
tial for foot pain and chronic secondary disability. In fact 
subjects with midfoot OA experience foot pain which 
deeply limits their participation in walking and weight-
bearing activities. 
The etiology of foot OA is still poorly understood, 
in fact only a few studies in international literature have 
highlighted major risk factors for developing foot OA 
[13,16-21]. It has been linked to trauma, sport injuries, in-
flammatory arthropathy, mechanical stress and idiopathic 
osteoarthritis [13]. Several authors have suggested that, 
similarly to other forms of non-traumatic OA, foot OA 
may be a result of abnormally high mechanical stress due 
to abnormal structural factors [14,15]. Davitt et al. hy-
pothesized that aberrant loading may be the result of toe 
length abnormalities, as patients with idiopathic midfoot 
OA were more likely to have a second toe longer than the 
great toe [16] . OA of the first metatarsophalangeal joint 
of the foot, commonly referred to as hallux limitus or hal-
lux rigidus, is thought to be caused by the compression of 
the dorsal aspect of the joint during the propulsive phase 
of gait in people with an excessively wide first metatar-
sal, wide proximal phalanx and long sesamoids. Further-
more people with flat feet or high arches are at greater 
risk for developing foot OA. A recent research has indi-
cated that older people with radio-graphically-confirmed 
OA of the talonavicular joint and navicular-first cunei-
form joint have significantly flatter feet in association 
with a significant greater dynamic loading of the midfoot 
when walking [17-20]. Finally, Yu et al suggested that 
the aberrant loading may be a result of past shoe use or 
footwear, noting that chronic high-heel use increased the 
risk of midfoot OA [21].
In addition, general factors as aging and obesity seem 
to play a key role in the pathomechanism of OA. Ag-
ing determines the reduction of cartilage volume, prote-
oglycan content, cartilage vascularization, and cartilage 
perfusion leading to favorable conditions to initiate the 
OA process. Obesity increases the mechanical stress in 
weight-bearing joints, so it particularly affects lower 
limb joints. Furthermore it has been demonstrated that 
obese patients alter their movement strategies of every 
day movements causing important changes in joint bio-
mechanics. Both factors contribute to the degenerative 
process that involves joint cartilage [22-24].
Clinical features
The key feature of OA is the progressive destruction 
of joint cartilage that causes reduction of articular space, 
subcondral sclerosis, subcondral cysts, synovial phlogo-
sis and osteophyte formation.
The usual symptoms associated with foot OA include: 
pain and stiffness of the affected foot, swelling near the 
affected joint, limited range of motion, difficulty in walk-
ing and bony protrusions. There are 28 bones and more 
than 30 joints in the human foot. The foot joints that are 
most commonly affected by osteoarthritis include:
• the 3 joints of the hindfoot (talocalcaneal joint, tal-
onavicular joint, calcaneocuboid joint)
• the midfoot (metatarsocuneiform joint)
• the great toe (first metatarsophalangeal joint)
OA releated pain diminishes the quality of life and 
limits physical functions. Patients have problem in doing 
housework as well as leisure activities [25,26]. In addi-
tion severe OA leads to deformities that typically affect 
the metatarsophalangeal joint causing significant limita-
tion of motion and function of feet [27]. Structural altera-
tions of the first metatarsophalangeal joint are described 
as either hallux limitus or hallux rigidus. The term used 
depends on the magnitude of available joint motion and 
the severity of joint degeneration. Hallux limitus is char-
acterized by restricted sagittal plane motion (primarily 
dorsiflexion) caused by periarticular osteophytes; where-
as hallux rigidus displays an absence of joint motion due 
to end stage degenerative joint disease and subsequent 
joint ankylosis. Although the terms are often used inter-
changeably, hallux rigidus has been adopted by the World 
Health Organization in the International Classification of 
Diseases [28,29]. 
Foot joints can even be affected by a rare form of OA 
that is characterized by erosions. Erosive OA has a poor 
clinical outcome. Patients experience several inflamma-
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tory episodes due to cartilage debris that activate the in-
flammatory process resulting in progressive joint damage 
and structural change [30].
Diagnosis
Physical examination can detect swelling, bone spurs 
or other deformities, limited range of motion and pain 
which occurs with movement. However, to define the di-
agnosis conventional radiographs are required to assess 
typical alterations found in foot OA joints. 
Different radiographic scales to identify and quantify 
foot OA exist, but the most frequently used is the one 
elaborated by Kellgren and Lawrence. This scale ranges 
from 0 to 4: 0 corresponding to absence of OA features 
and 4 to severe OA. 
The radiological features usually examined are: 
1) The formation of osteophytes on the joint margins 
or, in the case of the knee joint, on the tibial spines.
2) Periarticular ossicles; in particular at the level of 
distal and proximal interphalangeal joints.
3) Narrowing of joint cartilage associated with scle-
rosis of subchondral bone.
4) Small pseudocystic areas with sclerotic walls situ-
ated usually in the subchondral bone.
5) Altered shape of the bone ends, particularly in the 
head of femur [31]. 
In 2007 Menz at al [32] presented an atlas of radio-
graphic features of OA in commonly affected joints of 
the foot based on observations of osteophytes and joint 
space narrowing. The aim was to standardize the docu-
mentation and interpretation of foot OA for epidemiolog-
ical studies and clinical trials. Authors suggested a foot 
radiography protocol to identify OA. According to them 
weight-bearing dorso-plantar and lateral radiographic 
projections have to be performed in order to document 
osteophytes and joint space narrowing from both, in fact 
it was evident that the dorso-plantar projection provided 
the greatest clarity for some joints, whereas the lateral 
projection was the most suitable for others. The atlas was 
demonstrated to be acceptably reliable, and considered 
useful to document features in individual joints or to cal-
culate a global foot OA score [32].
Recently many researchers have described the im-
portance of ultrasonography (US) in evaluating joints 
and periarticular structures [33]. In the past decades the 
impressing technological development of US machines 
has encouraged the application of US in rheumatologi-
cal clinical practice as a sensitive and bedside imaging 
technique. It has even been included in the classification 
criteria for polymyalgia rheumatica in 2012 [33-35]. US, 
differently from radiography, can detect inflammation, 
cartilage reduction and even early erosions. The existing 
literature dealing with the ultrasonographic assessment 
of foot has focused on several rheumatic diseases as gout, 
early arthritis, rheumatoid arthritis and psoriatic arthritis 
[36-40]. However, even if US has been depicted as a val-
uable tool to assess the severity of osteoarthritic lesions 
and to accurately monitor their eventual progression, cur-
rently there is only one article that deals with the applica-
tion of US in foot OA [41]. In this study bilateral US of 
the midfoot and forefoot joints was performed assessing 
both inflammatory (joint effusion, synovial hypertro-
phy, local pathologic vascularization at Power Doppler, 
big toe bursitis) and structural (osteophytes, metatar-
sophalangeal joints subluxation) abnormalities. Authors 
concluded that US was a useful imaging technique for 
analysing both inflammatory and structural damage le-
sions at foot joints level in OA. In addition, it was dem-
onstrated to be more sensitive than clinical examination 
in the detection of inflammatory abnormalities [42].
 Finally, clinicians should consider magnetic reso-
nance imaging (MRI) too. MRI-based research is be-
coming increasingly more common in the OA research 
community. Novel MRI-based semiquantitative scoring 
systems have been proposed for the knee, hip and hand 
OA. MRI identifies earlier changes in OA joints com-
pared to standard radiography. A systematic review pub-
lished in 2011 examined the validity of MRI in OA and 
authors concluded that MRI is the current most valuable 
imaging tool for the assessment of OA due to its unique 
ability to visualize multiple individual tissue pathologies 
relevant in regard to pain and other clinical outcomes. In 
fact, MRI is able to detect bone marrow lesions, synovitis 
and effusion that have been related to pain. On the basis 
of these results, MRI is now recommended for clinical 
trials in terms of cartilage morphology assessment [43-
45].
Recent studies have focused their attention on the 
delayed gadolinium-enhanced magnetic resonance 
imaging of cartilage (dGEMRIC). Thanks to this par-
ticular technique it is possible to estimate the cartilage 
glycosaminoglican (GAG) content. It seems to be a 
promising and sensitive biomarker to reveal degenera-
tive modifications in cartilage quality in the very early 
stages of OA [46].
Treatment
Therapeutic strategies for foot OA are based on a 
wide spectrum of options and need to be always patient 
oriented. Treatment decisions should be made accord-
ing to a staged approach. Conservative treatment should 
be advised in early OA while more invasive procedures 
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particular the international research is focused in the 
treatment of OA of the big toe. A systematic review pub-
lished in 2010 described surgical options to treat hallux 
rigidus and/or limitus. Procedures include cheilectomy 
(removal of a bony lump at the joint margin), arthrodesis 
(surgical fusion of bones), arthroplasty (joint replace-
ment via remodelling or implant), osteotomy (cutting 
bone to shorten, lengthen or realign), soft tissue release 
and sesamoid release or excision [57-59].
Conclusions
Foot OA is a common musculoskeletal disorder that 
particularly affects older people worsening their quality 
of life. The joint most frequently involved in the degen-
erative progression of OA is the first metatarsophalan-
geal one. The pathogenesis and risk factors for foot OA 
need to be further investigated. US and MRI are gain-
ing importance in the diagnostic pathway of OA, even if 
conventional radiology must still be referred as the “gold 
standard” imaging technique. Therapeutic strategy for 
foot OA, involving conservative and invasive treatments, 
should always be related to the OA stage in the single pa-
tient. New researches dealing with the treatment of foot 
OA are required in order to make the best decisions for 
the management of this articular degenerative disease. 
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